Castellani MR - Search Results

1

Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patients.

Bogni A, Cortinois A, Grasselli G, Seregni E, Crippa F, Castellani MR, Bombardieri E. Bogni A, et al. Among authors: castellani mr. J Biol Regul Homeost Agents. 1994 Oct-Dec;8(4):121-5. J Biol Regul Homeost Agents. 1994. PMID: 7660854

2

Single determination of CA 15.3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer.

Crippa F, Bombardieri E, Seregni E, Castellani MR, Gasparini M, Maffioli L, Pizzichetta M, Buraggi GL. Crippa F, et al. Among authors: castellani mr. J Nucl Biol Med (1991). 1992 Jan-Mar;36(1):52-5. J Nucl Biol Med (1991). 1992. PMID: 1450226

3

Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?

Bombardieri E, Martinetti A, Miceli R, Mariani L, Castellani MR, Seregni E. Bombardieri E, et al. Among authors: castellani mr. Eur J Nucl Med. 1997 Nov;24(11):1349-55. doi: 10.1007/s002590050159. Eur J Nucl Med. 1997. PMID: 9371866 Clinical Trial.

4

Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues.

Chiti A, van Graafeiland BJ, Savelli G, Ferrari L, Seregni E, Castellani MR, Bombardieri E. Chiti A, et al. Among authors: castellani mr. Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S190-4. Ital J Gastroenterol Hepatol. 1999. PMID: 10604128 Clinical Trial.

5

Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.

Castellani MR, Chiti A, Seregni E, Bombardieri E. Castellani MR, et al. Q J Nucl Med. 2000 Mar;44(1):77-87. Q J Nucl Med. 2000. PMID: 10932604

6

Gallium scan in adolescents and children with Hodgkin's disease (HD). Treatment response assessment and prognostic value.

Castellani MR, Cefalo G, Terenziani M, Aliberti G, Maccauro M, Alessi A, Villano C, Bombardieri E. Castellani MR, et al. Q J Nucl Med. 2003 Mar;47(1):22-30. Q J Nucl Med. 2003. PMID: 12714951 Free article.

7

Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results.

Seregni E, Maccauro M, Coliva A, Castellani MR, Bajetta E, Aliberti G, Vellani C, Chiesa C, Martinetti A, Bogni A, Bombardieri E. Seregni E, et al. Among authors: castellani mr. Q J Nucl Med Mol Imaging. 2010 Feb;54(1):84-91. Q J Nucl Med Mol Imaging. 2010. PMID: 20168290 Free article. Clinical Trial.

8

(131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy.

Castellani MR, Seghezzi S, Chiesa C, Aliberti GL, Maccauro M, Seregni E, Orunesu E, Luksch R, Bombardieri E. Castellani MR, et al. Q J Nucl Med Mol Imaging. 2010 Feb;54(1):100-13. Q J Nucl Med Mol Imaging. 2010. PMID: 20168292 Free article.

9

Diagnostic procedures in the follow-up of patients affected by MEN type 2.

Seregni E, Pallotti F, Mattavelli F, Ferrari L, Martinetti A, Aliberti G, Villano C, Castellani MR, Bombardieri E. Seregni E, et al. Among authors: castellani mr. Tumori. 2003 Sep-Oct;89(5):563-5. doi: 10.1177/030089160308900524. Tumori. 2003. PMID: 14870788 Review.

10

Role of bone scan in breast cancer follow-up.

Maffioli L, Zambetti M, Castellani MR, Bombardieri E. Maffioli L, et al. Among authors: castellani mr. Tumori. 1997 Mar-Apr;83(2):547-9. doi: 10.1177/030089169708300213. Tumori. 1997. PMID: 9226017 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters